Red Yeast Rice and Cholesterol: What the Evidence Says

Red Yeast Rice and Cholesterol has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systemat

3 min read · 572 wordsReviewed May 2026
Close-up of black rice and assorted seeds in ceramic bowls. Perfect for healthy eating themes. - Evidence evidence guide for Red Yeast Rice and Cholesterol: What the Evidence Says
Photo by Robert Bykowski on Pexels · Pexels License

Quick Answer

Red Yeast Rice and Cholesterol has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence aware guidance rather than medical advice.

Key Takeaways

  • 01This page is generated only from sources stored in the Migaku evidence knowledge base.
  • 02Current evidence mix: 1 systematic review, 1 narrative review.
  • 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
  • 04This article is educational and does not replace care from a qualified clinician.

Red Yeast Rice and Cholesterol: What the Evidence Says

Quick Answer

Red Yeast Rice and Cholesterol has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

  • This page is generated only from sources stored in the Migaku evidence knowledge base.
  • Current evidence mix: 1 systematic review, 1 narrative review.
  • Claims should be interpreted with the source type, study design, population, and publication date in mind.
  • This article is educational and does not replace care from a qualified clinician.

Evidence Map

Source Evidence type Level Date Identifier
Impact of Monacolin K-Containing Supplements on Lipid Profile: A Meta-Analysis of Randomised Controlled Trials. systematic review 1 2026-03-01 10.1002/edm2.70166
Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications narrative review 3 2026-03-12 10.3390/biomedicines14030646

What The Sources Report

  • Conclusion These results highlight the potential of monacolin K as a promising adjunct therapy for hypercholesterolemia management, especially for patients who have not achieved LDL-C targets with standard care or are intolerant to or unwilling to use statin therapy. [Jamialahmadi T (2026); evidence level 1]
  • Background Natural products have gained attention as alternative strategies for managing dyslipidemia, particularly in individuals who are resistant or unwilling to use conventional pharmacotherapies. [Jamialahmadi T (2026); evidence level 1]
  • The concept of metabolic syndrome was first introduced in 1988 as "Syndrome X" to describe the frequent clustering of insulin resistance with metabolic abnormalities that increase the risk of type 2 diabetes mellitus and cardiovascular disease. [Starvaggi Josè (2026); evidence level 3]
  • This definition identifies metabolic syndrome based on the presence of at least three of the following components: increased waist circumference (population specific), hypertriglyceridemia and/or reduced HDL cholesterol, elevated blood pressure, and impaired fasting glucose. [Starvaggi Josè (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For red yeast rice cholesterol meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

  • Jamialahmadi T (2026). Impact of Monacolin K-Containing Supplements on Lipid Profile: A Meta-Analysis of Randomised Controlled Trials.. DOI: 10.1002/edm2.70166. PMCID: PMC12900892. PMID: 41681060. https://pmc.ncbi.nlm.nih.gov/articles/PMC12900892/
  • Starvaggi Josè (2026). Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications. DOI: 10.3390/biomedicines14030646. PMCID: PMC13024294. PMID: 41898291. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13024294/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.

FAQ

Frequently Asked Questions

M

Medically reviewed

Last reviewed May 22, 2026 by Migaku Evidence Review

← All GuidesSupplement Reference →